普米克令舒联合氨溴索雾化治疗在晚期新生儿肺炎患儿中的应用价值探讨

Discussion on application value of pulmicort respulas combined with ambroxol and inhalation method in late neonatal pneumonia

目的探讨普米克令舒联合氨溴索雾化在治疗晚期新生儿肺炎患儿中的应用价值。方法将晚期新生儿肺炎患儿随机分为实验组和对照组,对照组给予积极抗感染和对症治疗,实验组除外对照组处理还给予普米克令舒联合氨溴索雾化吸入治疗,比较两组患儿疗效、症状体征改善情况。结果实验组疗效整体优于对照组,且在退热时间、体征变化时间和住院时间上早于对照组,差异有统计学意义(P<0.05)。结论普米克令舒联合氨溴索雾化治疗晚期新生儿肺炎效果显著,能明显提高患儿治愈率,改善患儿临床症状和体征并缩短病程。

Objective To discuss the application value of pulmicort respulas combined with ambroxol with the inhalation method in late neonatal pneumonia. Methods The late neonatal pneumonia children were randomly divided into experimental group and control group, control group was given positive anti-infection and symptomatic treatment, the experimental group was given not only above but also pulmicort respulas combined with ambroxol with the inhalation method. Compared two groups of children with curative effect, the signs and symptoms improvement. Results Experimental group curative effect is better than that of control group whole, and signs of change is earlier than the control group in antifebrile time and hospital stay time, the difference is statistically significant （P〈0.05）. Conclusion The late neonatal pneumonia children in therapy of pulmicortrespulas combined with ambroxol with the inhalation method is remarkable, which can obviously increase the cure rate, improve the clinical signs and symptoms and shorten the course of the disease.